1
|
Huang J, Zhang M, Wu Y, Wang M, Zhu Y, Lin S. Fatty liver disease reverses the obesity paradox in chronic kidney disease stages 3-5: A follow-up study of NHANES III. Hepatol Commun 2022; 6:3132-3139. [PMID: 36125132 PMCID: PMC9592766 DOI: 10.1002/hep4.2086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 08/04/2022] [Accepted: 08/16/2022] [Indexed: 12/14/2022] Open
Abstract
High body mass index (BMI) has been associated with better survival in patients with end-stage kidney disease. Individuals with fatty liver disease (FLD) have a higher risk of chronic kidney disease. It remains unclear whether the survival benefit of high BMI in patients with chronic kidney disease is present when there is concomitant FLD. This study used the data set from the Third American National Health and Nutrition Examination Survey and the corresponding survival data. The Cox proportional hazards model was used to evaluate the effect of BMI on mortality. A total of 12,445 participants were included. The prevalence of FLD was 39.8%. The median follow-up time (with interquartile range) was 22.8 (20.8-24.8) years. During this period, 3749 (30.1%, 14.4 of 1000 person-year) deaths were observed. Among these, 1169 (31.2%) died within the first 10 years. The Cox regression analysis showed that the BMI level was not associated with 25-year mortality in patients with decreased glomerular filtration rate (GFR < 60 ml/min/1.73 m2 ), but 10-year mortality was significantly lower in patients with BMI ≥ 25 kg/m2 than in those with BMI < 25 kg/m2 (p = 0.049). Multivariate analysis showed BMI ≥ 25 kg/m2 was an independent protective factor for 10-year mortality (hazard ratio [HR] 0.691, 95% confidence interval [CI] 0.559-0.856; p = 0.001). This protective effect of higher BMI was lost in patients with FLD (HR 0.884, 95% CI 0.585-1.335; p = 0.557) but persisted in the non-FLD group (HR 0.625, 95% CI 0.479-0.816; p = 0.001). The survival benefit of overweight/obesity for patients with decreased GFR, which was attenuated by the presence of FLD, only existed in the first decade.
Collapse
Affiliation(s)
- Jiaofeng Huang
- Department of Hepatology, Hepatology Research Institutethe First Affiliated Hospital, Fujian Medical UniversityFuzhouChina,Fujian Clinical Research Center for Liver and Intestinal DiseasesFuzhouChina
| | - Min Zhang
- Department of NephrologyHuashan Hospital, Fudan UniversityShanghaiChina
| | - Yinlian Wu
- Department of Hepatology, Hepatology Research Institutethe First Affiliated Hospital, Fujian Medical UniversityFuzhouChina,Fujian Clinical Research Center for Liver and Intestinal DiseasesFuzhouChina
| | - Mingfang Wang
- Department of Hepatology, Hepatology Research Institutethe First Affiliated Hospital, Fujian Medical UniversityFuzhouChina,Fujian Clinical Research Center for Liver and Intestinal DiseasesFuzhouChina
| | - Yueyong Zhu
- Department of Hepatology, Hepatology Research Institutethe First Affiliated Hospital, Fujian Medical UniversityFuzhouChina,Fujian Clinical Research Center for Liver and Intestinal DiseasesFuzhouChina
| | - Su Lin
- Department of Hepatology, Hepatology Research Institutethe First Affiliated Hospital, Fujian Medical UniversityFuzhouChina,Fujian Clinical Research Center for Liver and Intestinal DiseasesFuzhouChina
| |
Collapse
|
2
|
Lin S, Araujo C, Hall A, Kumar R, Phillips A, Hassan M, Engelmann C, Quaglia A, Jalan R. Presence of multilobular necrosis on liver biopsy identifies corticosteroid responsiveness in acute indeterminate hepatitis. Liver Int 2022; 42:853-863. [PMID: 34936189 DOI: 10.1111/liv.15144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 11/29/2021] [Accepted: 12/15/2021] [Indexed: 02/13/2023]
Abstract
BACKGROUND AND AIMS Treatment of patients with severe indeterminate hepatitis (IAH) is an unmet need. Corticosteroids are often used in the management of these patients but criteria for the selection of patients for this intervention are arbitrary. The aims of this study were to analyse the clinical and pathological features of patients with IAH to define predictors of corticosteroid responsiveness. METHODS This study included consecutive patients with acute indeterminate hepatitis admitted to a single hospital and underwent a liver biopsy. The clinical manifestation and histopathological features of steroid and non-steroid groups were compared and their relationship with corticosteroids response was evaluated. RESULTS Forty-eight patients were included, 24 (50%) recovered and the other half underwent liver transplantation or died within 3-months. Of the 48 cases, 24 received corticosteroids (initial dose of 45 ± 12 mg prednisolone). Corticosteroids were initiated 2.7 ± 3.8 days after admission. Liver biopsy was performed 2-days (median, IQR 1-3) after admission. Fifteen (62.5%) patients receiving corticosteroids survived without transplantation compared with 9 (37.5%) that did not receive steroids (P = .149). In those with multilobular necrosis, 50% reduction in the death/transplantation rate was observed after steroid treatment (P = .018). In patients without multilobular necrosis and with or without perivenulitis, corticosteroids did not impact the outcome. Response to corticosteroids was independent of the MELD score. CONCLUSIONS The presence of multilobular necrosis on liver biopsy helps identify a subgroup of IAH cases who may benefit from the administration of corticosteroids.
Collapse
Affiliation(s)
- Su Lin
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK.,Department of Hepatology, Hepatology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Catarina Araujo
- Department of Cellular Pathology, Royal Free Hospital, London, UK.,Anatomical-Pathology Department, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal
| | - Andrew Hall
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK.,Department of Cellular Pathology, Royal Free Hospital, London, UK.,Sheila Sherlock Liver Center, Royal Free London NHS Foundation Trust, London, UK
| | - Rahul Kumar
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK.,Department of Gastroenterology and Hepatology, Duke-NUS academic Medical Centre, Changi General Hospital, Singapore, Singapore
| | - Alexandra Phillips
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK
| | - Mohsin Hassan
- Department of Hepatology and Gastroenterology, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Cornelius Engelmann
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK.,Department of Hepatology and Gastroenterology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.,Section Hepatology, Clinic for Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Alberto Quaglia
- Department of Cellular Pathology and UCL cancer Institute, Royal Free Hospital, London, UK
| | - Rajiv Jalan
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK.,European Foundation for the Study of Chronic Liver Failure (EFCLIF), Barcelona, Spain
| |
Collapse
|
3
|
Lin S, Hall A, Kumar R, Quaglia A, Jalan R. Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis. J Hepatol 2022; 76:485-487. [PMID: 34453964 DOI: 10.1016/j.jhep.2021.08.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Accepted: 08/19/2021] [Indexed: 12/15/2022]
Affiliation(s)
- Su Lin
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK; Department of Hepatology, Hepatology Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China, 350001
| | - Andrew Hall
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK; Department of Cellular Pathology, Royal Free Hospital, London, UK; Sheila Sherlock Liver Center, Royal Free London NHS Foundation Trust, UK
| | - Rahul Kumar
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK; Department of Gastroenterology and Hepatology, Duke-NUS academic Medical Centre, Changi General Hospital, Singapore
| | - Alberto Quaglia
- Department of Cellular Pathology and UCL cancer Institute, Royal Free Hospital, London, UK
| | - Rajiv Jalan
- Liver failure Group, Institute for Liver and Digestive Health, Division of Medicine, University College London Medical School, Royal Free Hospital, London, UK; European Foundation for the Study of Chronic Liver Failure (EFCLIF), Barcelona, Spain.
| |
Collapse
|